Du Ping, Cristarella Tiffany, Goyer Camille, Moride Yola
Global Evidence and Outcomes, Takeda Development Center Americas, Inc., Cambridge, MA, USA.
YolaRX Consultants Inc., Montreal, QC, Canada.
J Blood Med. 2024 Aug 14;15:363-386. doi: 10.2147/JBM.S464365. eCollection 2024.
Congenital (cTTP) and immune-mediated (iTTP) thrombotic thrombocytopenic purpura are serious and rare clotting disorders resulting from a deficiency in the ADAMTS13 enzyme. A systematic review was conducted using the Ovid MEDLINE & Embase databases to synthesize the epidemiology and burden of cTTP and iTTP worldwide (from January 1, 2010, to February 6, 2020, with an update that covered the period January 1, 2020-February 11, 2022). Outcomes of interest were incidence and prevalence of TTP, incidence of acute episodes, mortality, burden of illness (eg complications, healthcare utilization, patient-reported outcomes) and disease management. A total of 221 eligible observational studies were included. The incidence rate of acute episodes ranged from 0.19-0.35 person-years in adult patients with cTTP, and 1.81-3.93 per million persons per year for iTTP in the general population. Triggers of acute episodes were similar for cTTP and iTTP, with pregnancy and infection the most commonly observed. Exacerbation in patients with iTTP varied widely, ranging from 2.4-63.1%. All-cause mortality was observed in 0-13.4% of patients with cTTP, across studies and follow-up periods, and in 1.1% (median follow-up: 0.4 years) to 18.8% (1 year) of patients with iTTP during acute episodes. Cardiovascular, renal, and neurological disease were common complications. TTP also led to work disturbances, feelings of anxiety and depression, and general activity impairment. TTP treatment regimens used were generally reflective of current treatment guidelines. The evidence identified describes a high patient burden, highlighting the need for effective treatment regimens leading to improvements in outcomes. Considerable evidence gaps exist, particularly for disease epidemiology, patient-reported outcomes, costs of disease management, and associated healthcare resource utilization. This review may help increase disease awareness and highlights the need for additional real-world studies, particularly in geographical regions outside the United States and Western Europe.
先天性(cTTP)和免疫介导性(iTTP)血栓性血小板减少性紫癜是由于ADAMTS13酶缺乏导致的严重且罕见的凝血障碍。使用Ovid MEDLINE和Embase数据库进行了一项系统综述,以综合全球范围内cTTP和iTTP的流行病学及疾病负担(从2010年1月1日至2020年2月6日,并更新至涵盖2020年1月1日至2022年2月11日期间的数据)。感兴趣的结果包括TTP的发病率和患病率、急性发作的发生率、死亡率、疾病负担(如并发症、医疗保健利用情况、患者报告的结果)以及疾病管理。总共纳入了221项符合条件的观察性研究。成年cTTP患者急性发作的发生率为每0.19 - 0.35人年,普通人群中iTTP的发生率为每年每百万人1.81 - 3.93例。cTTP和iTTP急性发作的诱因相似,妊娠和感染是最常见的。iTTP患者病情加重的情况差异很大,范围为2.4% - 63.1%。在各项研究及随访期间,0 - 13.4%的cTTP患者出现全因死亡率,iTTP患者在急性发作期间的全因死亡率为1.1%(中位随访时间:0.4年)至18.8%(1年)。心血管、肾脏和神经系统疾病是常见并发症。TTP还导致工作障碍、焦虑和抑郁情绪以及日常活动受损。所使用的TTP治疗方案总体上符合当前治疗指南。所确定的证据描述了较高的患者负担,凸显了需要有效的治疗方案以改善治疗结果。存在相当多的证据空白,特别是在疾病流行病学、患者报告的结果、疾病管理成本以及相关医疗资源利用方面。本综述可能有助于提高对该疾病的认识,并强调需要开展更多真实世界研究,特别是在美国和西欧以外的地理区域。